» Articles » PMID: 35113368

Characteristics of Pooled Wharton's Jelly Mesenchymal Stromal Cells (WJ-MSCs) and Their Potential Role in Rheumatoid Arthritis Treatment

Overview
Publisher Springer
Specialty Cell Biology
Date 2022 Feb 3
PMID 35113368
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Mesenchymal stromal cells (MSC) from Wharton's jelly of umbilical cord is primitive and serve as an inexhaustible source of stem cells with greater potential in clinics. The existence of heterogeneity among the donor MSCs makes it difficult to predict the properties and clinical outcome of WJ-MSCs. We developed a strategy to minimize the donor to donor heterogeneity and produce consistency in biological properties by pooling three individual donors WJ-MSCs. Further, evaluated the effectiveness of the pooled MSCs in regulating the disease severity of Rheumatoid arthritis (RA) in animal models.

Methods: WJ-MSCs were isolated from umbilical cord obtained from different donors, characterised and pooled based on the gender of baby. The biological properties of the pooled WJ-MSCs were compared to the individual WJ-MSCs. Further, the pooled WJ-MSCs were analysed for their safety profile in both in vitro and in vivo settings. The efficiency of pooled WJ-MSCs in regulating RA pathogenesis was also analysed in mice models of Collagen induced arthritis (CIA).

Results: We identified differences in proliferation capacity, pro inflammatory gene expression levels among individual WJ-MSCs isolated from different donors and the variation is also attributed to gender difference. WJ-MSCs pooled and cultured from different donor's exhibit all the MSC characteristics and exhibited superior immunosuppressive capabilities. In the in vivo toxicity study, pooled MSCs are found to be safe, and further in the RA preclinical studies, they were found to decrease the disease severity in these animals.

Conclusions: Pooled WJ-MSCs reduces heterogeneity of individual donors and have superior immunosuppressive property. It is also effective in reducing the disease severity in the experimental animal models of RA.

Citing Articles

The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.

cesnik A, Svajger U Front Cell Dev Biol. 2024; 12:1400347.

PMID: 39129786 PMC: 11310176. DOI: 10.3389/fcell.2024.1400347.


Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs.

Kannan S, Gokul Krishna S, Gupta P, Kolkundkar U Sci Rep. 2024; 14(1):12654.

PMID: 38825595 PMC: 11144708. DOI: 10.1038/s41598-024-62544-8.


Mesenchymal Stromal Cells: New Generation Treatment of Inflammatory Bowel Disease.

Wei S, Li M, Wang Q, Zhao Y, Du F, Chen Y J Inflamm Res. 2024; 17:3307-3334.

PMID: 38800593 PMC: 11128225. DOI: 10.2147/JIR.S458103.


Mesenchymal Stromal Cells: Heterogeneity and Therapeutical Applications.

Ouzin M, Kogler G Cells. 2023; 12(16).

PMID: 37626848 PMC: 10453316. DOI: 10.3390/cells12162039.


Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy.

Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J J Nanobiotechnology. 2022; 20(1):432.

PMID: 36183106 PMC: 9526331. DOI: 10.1186/s12951-022-01636-x.

References
1.
Horwitz E, Dominici M . How do mesenchymal stromal cells exert their therapeutic benefit?. Cytotherapy. 2008; 10(8):771-4. DOI: 10.1080/14653240802618085. View

2.
Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y . Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med. 2014; 34(3):695-704. PMC: 4121354. DOI: 10.3892/ijmm.2014.1821. View

3.
FRIEDENSTEIN A, PETRAKOVA K, Kurolesova A, Frolova G . Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968; 6(2):230-47. View

4.
Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M . Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells. 2005; 23(8):1105-12. DOI: 10.1634/stemcells.2004-0330. View

5.
Zuk P, Zhu M, Mizuno H, Huang J, Futrell J, Katz A . Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7(2):211-28. DOI: 10.1089/107632701300062859. View